著者

河本 圭司

出版者

近畿脳腫瘍病理検討会

雑誌

Neuro-Oncologyの進歩 (ISSN:18800742)

巻号頁・発行日

vol.19, no.1, pp.45-48, 2010-12-01 (Released:2014-04-28)

著者

播磨 洋子 永田 憲司 寒川 光治 澤田 敏

出版者

近畿脳腫瘍病理検討会

雑誌

Oncologyの進歩 (ISSN:09176969)

巻号頁・発行日

vol.11, no.1, pp.12-16, 2001 (Released:2012-10-29)

参考文献数

20

---

Studies of loss of heterozygosity (LOH) in cervical carcinoma have reported a high frequency of allelic deletions affecting 3p21.3,6p21.2,17p13.1, and 18q21.2. Our study explored whether human papilloma virus (HPV)and LOH on chromosome 3p21.3,6p21.2,17p13.1, and 18q21.2 are associated with treatment outcome in patients with cervical cancer after radiotherapy. A total of 65 patients with cervical cancer (stage I-ive patients, II-eight, III-34, IV-16, recurrence-two) were included in this study. Tumors and normal DNA were analyzed by polymerase chain reaction (PCR) for genetic losses at ten polymorphic microsatellite loci. The presence of HPV and its type were analyzed by PCR-based assay using the consensus primers for L1 and E6 region. Chromosomes 3p21.3,6p21.2,17p13. land 18q21.2 were involved in the LOH in 23.1%,41.5%%,33.8%, and 23.1% of the informative carcinomas, respectively. HPV-positive tumors were found in 73.8% of the patients. Overall survival was significantly worse for the patients with LOH on chromosome 6p21.2 and 18q21.2 as compared to those without LOH (P=0.006, and P=0.007, respectively). The HPV-negative patients survived significantly shorter compared to the HPV-positive patients in the overall survival (P=0.01). The results of this study suggest that absence of HPV infection, LOH on 6p21.2, and LOH on 18q21.2 are the most important determinants of outcome of patients with cervical carcinoma after radiotherapy.

著者

篠山 隆司 田中 一寛 西原 賢在 長嶋 宏明 甲村 英二

出版者

近畿脳腫瘍病理検討会

雑誌

Neuro-Oncologyの進歩 (ISSN:18800742)

巻号頁・発行日

vol.23, no.3, pp.09-15, 2017-02-08 (Released:2017-02-08)

参考文献数

28

---

The diagnosis of primary central nervous system lymphoma (PCNSL) is commonly obtained via a stereotactic biopsy. The use of radiographic images (CT, MRI, and PET) frequently fails to distinguish PCNSLs from other brain diseases. Flow-cytometry based and cytological analyses of cerebrospinal fluid (CSF) are useful for the evaluation of leptomeningeal PCNSLs, however, these tests are usually insensitive to focal PCNSLs.Recently, several useful diagnostic biomarkers in CSF for PCNSL were reported. Among these CSF biomarkers, CSF interleukin-10 (IL-10) and C-X-C motif ligand 13 (CXCL13) are the most promising useful diagnostic biomarkers for PCNSLs. Both CSF IL-10 and CXCL13 have high sensitivity and specificity for diagnosing in PCNSL patients, and moreover, the combination IL-10 and CXCL13 is quite highly specific tool for diagnosis of PCNSL. However, there are several problems in these markers. Our goal in this review is to highlight and update the diagnostic biomarkers in CSF for the patients with PCNSLs, and describe future directions.

著者

沖田 典子 丸野 元彦 吉澤 秀憲 鈴木 強

出版者

近畿脳腫瘍病理検討会

雑誌

Neuro-Oncologyの進歩 (ISSN:18800742)

巻号頁・発行日

vol.20, no.1, pp.50-53, 2014 (Released:2014-05-07)

参考文献数

19

---

Glioblastoma is the most common and malignant primary brain tumor. Factors such as age, Karnofsky performance score (KPS), and extent of resection have been shown to be prognostic for survival in newly diagnosed malignant glioma patients. O6-methylguanine DNA-methyltransferase (MGMT) promoter methylation status is also a prognostic factor in newly diagnosed glioblastoma patients. IDH1 mutation detected by direct sequencing or by immunochemistry of its more frequent form has been reported to be a strong and independent prognostic factor in gliomas whatever the grade. 1p/19q deletions are prognostic factors in oligodendroglial tumors and predict better survival after both chemotherapy and radiotherapy. Expression of immunohistochemical staining for α-Internexin was reported to correlate with 1p/19q deletions.We have two glioblastoma long term survivors and these cases showed similar clinical and radiological presentation with other glioblastoma cases who relapsed and survived less than a year. We investigated immunohistochemical staining for IDH1-R132H, MGMT and α-Internexin in these two cases and all stainings were negative. We should have more attention for other prognostic factors in glioblastoma long term survivors.

著者

森内 秀祐

出版者

近畿脳腫瘍病理検討会

雑誌

Neuro-Oncologyの進歩 (ISSN:18800742)

巻号頁・発行日

vol.18, no.1, pp.1-6, 2009-11-01 (Released:2014-04-22)

参考文献数

8

---

We experienced 7 cases of immunosuppressed patients with enhancing intracerebral lesions on CT and MRI at our hospital in the period between 2004 and 2008. The cases included 6 patients infected with HIV and 1 rheumatoid arthritis patient. Patients aged between 40 and 56, and they consisted of 6 males and 1 female. HIV patients are generally first treated for HIV associated benign diseases or infectious diseases, including Cryptococcus infections, fungal infections, and so on. When these treatments are not effective, a differential diagnosis for malignant lymphoma is required before considering radiation therapy and chemotherapy. We performed open biopsies on all cases, and used a computer aided navigation system to assist in our minimal invasive surgery. The average total volume of specimens attained by biopsy was about 1cm3 and enough to undertake an immunohistochemical study, a flow cytometric study, and a gene translication study of gamma immunoglobulin genes. The final diagnosis of the 7 cases were diffuse large B cell lymphoma, adult T cell lymphoma, toxoplasmosis, a lymphoproliferative state due to an EB virus infection, and immuno-reconstruction syndrome after treatments for HIV. Despite the fact that CT and MRI image studies were similar between patients, final diagnosis differed and included malignant diseases. In conclusion, we consider it difficult to make an accurate diagnosis of CT and MRI enhancing intracerebral lesions in immunosuppressed patients, and regard it as very important to undertake open biopsies to make a final diagnosis and to differentiate between a variety of disorders in such patients.

出版者

近畿脳腫瘍病理検討会

雑誌

Oncologyの進歩 (ISSN:09176969)

巻号頁・発行日

vol.10, no.1, pp.59-60, 2000 (Released:2012-10-29)